Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Mylan Inc. : Mylan Launches First Generic Version of Doryx® 150 mg

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/30/2012 | 08:20pm CEST

PITTSBURGH, April 30, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg, following a favorable decision by the U.S. District Court for the District of New Jersey in a patent infringement lawsuit brought by Warner Chilcott. The Court held, after trial, that Mylan's product does not infringe the subject patent. Mylan is shipping product immediately.

Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg is the generic version of Mayne Pharma's Doryx(®) 150 mg product (marketed by Warner Chilcott), and is a tetracycline-class antimicrobial.

Doxycycline Hyclate DR Tablets, 150 mg, had U.S. sales of approximately $264.1 million for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

SOURCE Mylan Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on MYLAN INC
05/23 MYLAN NV : Launches First Generic Doryx® Delayed-Release Tablets, 200 mg
05/17 MYLAN NV : Updates Timetable for Commencement of Acceptance Period for Offer for..
05/13 MYLAN NV : to Acquire Renaissance's Leading Topicals-Focused Specialty and Gener..
05/12DJPerrigo Loss Deepens
05/12 MYLAN NV : Launches Generic Frova® Tablets
05/12DJPerrigo Loss Deepens
05/05 MYLAN NV : Launches Generic Apresoline® Injection
05/04 MYLAN NV : to Present at the Bank of America Merrill Lynch 19th Annual Health Ca..
05/03DJU.S. HOT STOCKS : Hot Stocks to Watch
05/03DJMylan Posts Better-Than-Expected Profit